Image
Optimizing Advanced Therapies in Ulcerative Colitis Is Your Practice Up to Date? A Focus on Clinical Evidence and Guideline Recommendations

Maria T. Abreu, MD; Jean-Frédéric Colombel, MD

This activity is jointly provided by Global Education Group and Integritas Communications.

 

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

 

Target Audience

The educational design of this activity addresses the needs of clinical gastroenterologists and specialist nurse practitioners and physician assistants involved in the treatment of patients with ulcerative colitis (UC).

Statement of Need/Program Overview

The introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of ulcerative colitis (UC). However, agents of the tumor necrosis factor (TNF) inhibitor class are limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the treatment of UC is complex and variable, there is a greater need to better understand the mechanistic profiles, clinical evidence, and placement of advanced, non-TNF inhibitor therapies within the management of moderate to severe disease.1 This IBD eHealth Source™, comprised of 4 chapters, will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate to severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals. Clinical data will be augmented with pertinent qualitative-research–derived insights from expert faculty to provide actionable recommendations for practicing clinicians.

Reference

1. Coskun M, Vermeire S, Nielsen OH. Trends Pharmacol Sci. 2017;38(2):127-142.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Appropriately assess disease severity and activity to identify high-risk patients with UC who may be candidates for advanced treatment with biologics or small molecule inhibitor agents
  • Describe guideline recommendations and clinical trial evidence surrounding induction and maintenance therapies for moderate-to-severe UC
  • Implement treat-to-target strategies that utilize objective measures of remission as well as patient reported outcomes (PROs) to reach patient-centered treatment goals
  • Translate evidence to informed therapeutic selection when evaluating the positioning of biologics and small molecule inhibitors for first-line induction, maintenance, or next-line therapy

Faculty

Maria T. Abreu, MD
Professor of Medicine
Professor of Microbiology and Immunology
Vice Chair of Research, Department of Medicine
Martin Kalser Chair in Gastroenterology
Director, Crohn’s & Colitis Center
Chair, IOIBD
University of Miami Miller School of Medicine
Miami, Florida

Jean-Frederic Colombel, MD
Professor of Medicine, Gastroenterology
Director, Inflammatory Bowel Disease Center
Icahn School of Medicine at Mount Sinai
New York, New York

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Term of Offering

This activity was released on October 15, 2021, and is valid for one year. Requests for credit must be made no later than October 15, 2022.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the posttest, and complete the program evaluation.

Fee Information& Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Maria T. Abreu, MD     Consultant/Independent Contractor: AbbVie Inc., Alimentiv, Arena Pharmaceuticals, Inc., Bellatrix Pharmaceuticals, Inc., Bristol Myers Squibb, Cosmo Bio USA, Eli Lilly and Company, Gilead Sciences, Inc., Imedex, LLC, Janssen Pharmaceuticals, Inc., Prometheus Biosciences, Takeda Pharmaceuticals U.S.A., Inc.; Grant/Research Support: Pfizer Inc., Prometheus Biosciences, Takeda Pharmaceuticals U.S.A., Inc.; Honoraria (general): AbbVie Inc., Bellatrix Pharmaceuticals, Inc., Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences, Inc., Janssen Ortho, LLC, Prometheus Biosciences; Honoraria (teaching, lecturing, or speaking): Alimentiv Inc., Arena Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Microba Life Sciences, PRIME Education, LLC, Takeda Pharmaceuticals U.S.A., Inc., UCB S.A.

Jean-Frederic Colombel, MD     Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Arena Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals, Galmed Research, Genentech, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Inc., Merck & Co., Inc., Microba Life Sciences, Novartis International AG, PBM Capital Group, Pfizer Inc., Sanofi S.A., Takeda Pharmaceuticals U.S.A., Inc., TiGenix, Vifor Pharma Group; Grant/Research Support: AbbVie Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc.; Stock Shareholder: Intestinal Biotech Development; Other/Royalty (lectures): AbbVie Inc., Amgen Inc., Allergan, Inc., Ferring Pharmaceuticals, Shire plc, Takeda Pharmaceuticals U.S.A., Inc.

The following planners and managers have no relevant financial relationships with ineligible companies:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Kim Rodriguez, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

System Requirements

PC
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

MAC
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 1.50

credit type AMA PRA

release 10/15/2021

expiration 10/15/2022

type eHealthSource